Shares of AbbVie Inc. ABBV rallied 1.34% to $185.72 Tuesday, on what proved to be an all-around positive trading session for ...

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Collaboration to leverage AbbVie's expertise in biotherapeutic drug development and commercialization together with ADARx's proprietary RNA technology to advance next-generation siRNA therapies ...

Gifting allows recipients to access the article for free. AbbVie is entering a collaboration and license option deal with ADARx Pharmaceuticals to develop a new type of RNA technology for disease ...

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) therapeutics across several disease areas. The collaboration and license ...

Investors with a lot of money to spend have taken a bullish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the trades showed up on publicly available ...

AbbVie snagged yet another spot among April’s highest TV ad spenders, as its Vraylar jumped two spots to eighth place with a $16.5 million outlay. Eli Lilly and Boehringer Ingelheim’s ...

May 14 (Reuters) - The U.S. Food and Drug Administration has approved AbbVie's (ABBV.N), opens new tab drug to treat adults with a type of lung cancer who have received previous treatment ...

These two policies could have major impacts on AbbVie, Lilly, and Johnson & Johnson. Investors often view Pharmaceutical stocks as safe havens during periods of market turbulence. Stock market ...

Google has updated its iconic 'G' logo for the first time in almost a decade. While the new logo retains the 'G' in the familiar Product Sans format, it introduces significant changes to the ...